A GLP-1 weight-loss drug can list for more than $1,000 a month — and almost nobody actually pays that. The gap between the pharmacy-counter price and what people really pay is enormous, and which price you get depends entirely on your situation: whether you have Medicare, commercial insurance, or no coverage at all. This hub maps every legitimate route, with current prices, so you can find the one that fits you.
It also does something the seller and telehealth pages won’t: it tells you, plainly and with no product to sell, how to spot a dangerous “cheap” option from a safe one. The lowest price is not always the right buy, and a price that looks too good usually is.
- Retail without insurance: roughly $1,000–$1,350/month for Wegovy, Ozempic, Zepbound, or Rybelsus
- Medicare (eligible Part D): $50/month via the GLP-1 Bridge, July 2026–December 2027
- Brand self-pay (uninsured): NovoCare (Wegovy) ~$199–$499; LillyDirect (Zepbound) ~$299–$449
- Compounded via licensed telehealth: often $99–$400/month — legal on a 503A basis, but quality varies
- Savings cards ($25/month): commercial insurance only — not for Medicare, Medicaid, or the uninsured
- Red flag: any price below about $90/month, or “FDA-approved compounded” claims (impossible)
What GLP-1 Drugs Actually Cost in 2026
The brand list prices are real, but they’re the number almost no one pays. Here’s the retail starting point before any program or discount:
| Drug | Active ingredient | Approx. retail/month | Approved for |
|---|---|---|---|
| Wegovy | Semaglutide | ~$1,349 | Weight management |
| Ozempic | Semaglutide | ~$998 | Type 2 diabetes |
| Rybelsus | Semaglutide (oral) | ~$1,000+ | Type 2 diabetes |
| Zepbound | Tirzepatide | ~$1,086 | Weight management |
| Mounjaro | Tirzepatide | ~$1,080 | Type 2 diabetes |
A pattern worth knowing: the drugs approved for weight management (Wegovy, Zepbound) are the ones the weight-loss programs below apply to. The diabetes-approved versions (Ozempic, Mounjaro, Rybelsus) are usually only covered by insurance when you have diabetes, and prescribing them off-label for weight loss is almost always denied. Same molecules, different rules.
Find Your Route by Coverage
The right pathway depends on how you’re covered. Start here:
If you have Medicare
If you have no coverage (cash-pay)
If safety is your worry
The Self-Pay and Compounded Landscape, Explained Honestly
If you’re paying cash, you have three legitimate tiers, and the seller pages rarely lay them out side by side without steering you toward whatever they sell.
| Tier | What it is | Typical monthly cost | The trade-off |
|---|---|---|---|
| Compounded (telehealth) | A licensed 503A pharmacy prepares it to your prescription | ~$99–$400 | Lowest cost; not FDA-approved as a finished product; quality varies by source |
| Manufacturer self-pay | NovoCare (Wegovy), LillyDirect (Zepbound) | ~$199–$499 | Brand-name, FDA-approved; pricier than compounded; refill timing rules apply |
| Retail + discount card | Pharmacy price with GoodRx or similar | ~$800–$1,000 | FDA-approved but the most expensive route; rarely the best deal |
One widely misunderstood point: the shortage-era version of cheap compounding — where pharmacies mass-produced copies because the brands were in shortage — ended in 2025 when the FDA declared the semaglutide and tirzepatide shortages resolved. Compounded GLP-1s did not disappear, but the lawful basis changed. Today a 503A pharmacy compounds a formulation tailored to a documented clinical need under a prescriber’s oversight. Any provider selling off-the-shelf compounded GLP-1 with no clinical justification — or claiming it’s “FDA-approved” — is operating outside that line.
Red flags when buying compounded GLP-1 online. Walk away if you see any of these:
- “FDA-approved compounded” claims — impossible; the FDA does not approve compounded drugs as finished products.
- Price below ~$90/month — the active-ingredient cost alone exceeds that, so something is being cut.
- Overseas shipping from China or India, or “research peptide” products not intended for human use.
- No prescriber oversight or refusal to name the partner pharmacy.
- Teaser pricing that jumps after the first month, or hidden membership and consultation fees on top of the drug price.
How to verify a compounding pharmacy: confirm its state pharmacy license, look for NABP Compounding Pharmacy Accreditation, and cross-check the FDA’s published warning letters before you buy. The FDA has issued dozens of warning letters to compounded-GLP-1 sellers since late 2025.
Why You May Not Be Able to Use a $25 Savings Card
You’ll see “$25 a month” advertised for Wegovy, Ozempic, and Zepbound. Read the fine print: those manufacturer savings cards require commercial insurance (employer or marketplace) that covers the drug. They are explicitly unavailable to anyone with Medicare, Medicaid, TRICARE, or VA coverage, and to the fully uninsured. So the cheapest-looking option is often the one most cost-burdened patients can’t use. If a card doesn’t apply to you, the routes that do are manufacturer self-pay, compounded, or — if you’re on Medicare — the GLP-1 Bridge.
Frequently Asked Questions
How we reviewed this page:
SunnyPharma follows strict sourcing guidelines and relies on primary government sources (CMS, FDA), peer-reviewed research, and established health-policy analysts (KFF). Pricing reflects published manufacturer, CMS, and independent analyst figures current as of June 2026; confirm current prices directly with each program.
Read our editorial policy →Sources & References
- GoodRx — Ozempic, Wegovy, and Zepbound retail price data. 2026.
- NovoCare — Wegovy and Ozempic self-pay pricing and Patient Assistance Program. Novo Nordisk, 2026.
- LillyDirect — Zepbound self-pay pricing. Eli Lilly, 2026.
- FDA — Human drug compounding, GLP-1 supply, and warning letters. 2025–2026.
- CMS — Medicare GLP-1 Bridge. 2026.
- NABP — Compounding Pharmacy Accreditation. 2026.